Skip to main content
. 2013 Jul 12;56(2):51–56.

Table 2. Adjuvant systemic therapy.

Number (%)
Endocrine therapy [n = 140] Tamoxifen ± LH-RH agonist 48 (34%)
Aromatase inhibitor 75 (54%)
Tamoxifen ± LH-RH agonist → Aromatase inhibitor 15 (10%)
Aromatase inhibitor → Tamoxifen 1 (1%)
Toremifene citrate 1 (1%)
Chemotherapy [n = 24] Anthracyclin 19 (79%)
Anthracyclin + Taxane 5 (21%)

LH-RH, luteinizing hormone-releasing hormone.